



2020 Target Therapy Forum
EGFR Question and Answer Panel
Updates on Combination Treatment of Osimertinib
(Tagrisso) and Ramucirumab (Cyramza)

**Dr. Jared Weiss-Associate Professor, Clinical Research,
Hematology/Oncology, University of North Carolina School of Medicine,
Faculty and Vice President of GRACE Board**

**Dr. Zofia Piotrowska-Medical Oncologist, Massachusetts General Hospital,
Associate Professor of Medicine, Harvard School of Medicine**

Dr. Jared Weiss: We have a question, what about osimertinib and Cyramza. So Cyramza is ramucirumab, I apologize if that perhaps the combination with first gen TKI should have been in my deck for balance. But I didn't feel a particular need to balance out something I'm not doing anyway in the more general theme. I believe there is an ongoing study of osimertinib and ramucirumab, and based on the favorable data and now approval of that combination with first-generation drug. I would call that on, on the list of things of high promise for ultimately changing a standard of care and a trial that is worthy of keeping one's eye on. But I'm not aware of any clinical data effect of the combo with Osi being out yet.

Dr. Zofia Piotrowska: No, I think we know both of the combinations with the VEGF targeted agents like ramucirumab or bevacizumab and with the chemotherapy combinations. I think what we're really lacking, you know, those studies were done just as osimertinib was being moved to the frontline. And what we're really lacking is any data so far on the combination of these different kind of potential additive agents to osimertinib. And I think it'll certainly be interesting to see there are studies, like you said, osimertinib with ramucirumab, osimertinib with bevacizumab, and osimertinib with chemotherapy. All of those are ongoing. And I, for one, am very excited to see the results, but currently outside of a clinical trial, I haven't been doing that. I think, you know, there's so many advantages to single agent osimertinib that it's hard to kind of, you know, to disrupt that quality of life and the ability to take a pill and come to us, hopefully infrequently.



Dr. Jared Weiss: I very much agree.